234 related articles for article (PubMed ID: 33923884)
1. Surgical Treatment of Pancreatic Ductal Adenocarcinoma.
Wei K; Hackert T
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33923884
[TBL] [Abstract][Full Text] [Related]
2. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
[TBL] [Abstract][Full Text] [Related]
3. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
4. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals.
Kulkarni NM; Mannelli L; Zins M; Bhosale PR; Arif-Tiwari H; Brook OR; Hecht EM; Kastrinos F; Wang ZJ; Soloff EV; Tolat PP; Sangster G; Fleming J; Tamm EP; Kambadakone AR
Abdom Radiol (NY); 2020 Mar; 45(3):729-742. PubMed ID: 31768594
[TBL] [Abstract][Full Text] [Related]
5. Borderline resectable pancreatic cancer.
Hackert T; Ulrich A; Büchler MW
Cancer Lett; 2016 Jun; 375(2):231-237. PubMed ID: 26970276
[TBL] [Abstract][Full Text] [Related]
6. [Progress in clinical research of pancreatic cancer: from "resection" to "cure"].
Shen J; Guo SW; Jin G
Zhonghua Wai Ke Za Zhi; 2019 Jan; 57(1):72-77. PubMed ID: 30612395
[TBL] [Abstract][Full Text] [Related]
7. Radiofrequency ablation of pancreatic ductal adenocarcinoma: The past, the present and the future.
Pandya GJ; Shelat VG
World J Gastrointest Oncol; 2015 Feb; 7(2):6-11. PubMed ID: 25685272
[TBL] [Abstract][Full Text] [Related]
8. Contemporary management of borderline resectable pancreatic ductal adenocarcinoma.
Lekka K; Tzitzi E; Giakoustidis A; Papadopoulos V; Giakoustidis D
Ann Hepatobiliary Pancreat Surg; 2019 May; 23(2):97-108. PubMed ID: 31225409
[TBL] [Abstract][Full Text] [Related]
9. Surgical and local treatment of hepatic metastasis in pancreatic ductal adenocarcinoma: recent advances and future prospects.
Jin T; Dai C; Xu F
Ther Adv Med Oncol; 2020; 12():1758835920933034. PubMed ID: 32636941
[TBL] [Abstract][Full Text] [Related]
10. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.
Kulkarni NM; Soloff EV; Tolat PP; Sangster GP; Fleming JB; Brook OR; Wang ZJ; Hecht EM; Zins M; Bhosale PR; Arif-Tiwari H; Mannelli L; Kambadakone AR; Tamm EP
Abdom Radiol (NY); 2020 Mar; 45(3):716-728. PubMed ID: 31748823
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer.
Klaiber U; Leonhardt CS; Strobel O; Tjaden C; Hackert T; Neoptolemos JP
Langenbecks Arch Surg; 2018 Dec; 403(8):917-932. PubMed ID: 30397779
[TBL] [Abstract][Full Text] [Related]
12. Neo-adjuvant therapy for pancreatic cancer: hope for the future.
Borazanci E; Sckolnik S; Amini A
Expert Rev Gastroenterol Hepatol; 2019 Jun; 13(6):579-589. PubMed ID: 30979348
[TBL] [Abstract][Full Text] [Related]
13. Conversion Surgery for Pancreatic Cancer-The Impact of Neoadjuvant Treatment.
Klaiber U; Hackert T
Front Oncol; 2019; 9():1501. PubMed ID: 31993372
[TBL] [Abstract][Full Text] [Related]
14. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
15. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
16. Vascular resection for locally advanced pancreatic ductal adenocarcinoma: analysis of long-term outcomes from a single-centre series.
Feo CF; Deiana G; Ninniri C; Cherchi G; Crivelli P; Fancellu A; Ginesu GC; Porcu A
World J Surg Oncol; 2021 Apr; 19(1):126. PubMed ID: 33866970
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
Front Oncol; 2020; 10():41. PubMed ID: 32083002
[TBL] [Abstract][Full Text] [Related]
18. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
19. Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection.
Ren W; Xourafas D; Ashley SW; Clancy TE
J Surg Res; 2021 Jan; 257():605-615. PubMed ID: 32947122
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival following total pancreatectomy and superior mesenteric-portal vein resection for pancreatic ductal adenocarcinoma: A case report.
Tong HX; Zhang L; Rong YF; Wang DS; Kuang TT; Xu XF; Lou WH; Jin DY
Oncol Lett; 2015 Jan; 9(1):318-320. PubMed ID: 25435983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
